Senseonics (SENS) Q1 2026 earnings review
Commercial Independence Costs a Fortune
Senseonics successfully transitioned U.S. commercial operations in-house from Ascensia, driving an impressive 87% YoY revenue growth to $11.7M and boosting gross margins to 59%. Management raised FY26 revenue guidance to $60-64M. However, the cost of independence was staggering: SG&A expenses quadrupled YoY to $30.2M, dwarfing total revenue and driving the quarterly net loss to a massive $32.3M. To fund this aggressive commercial transition and pipeline development, the company had to tap the markets for another $92M in equity dilution.
🐂 Bull Case
By eliminating Ascensia's revenue share, Senseonics captured the full value of its sales. Gross margin surged from 24% a year ago to 59% in 26Q1, establishing a highly scalable unit economics model.
Direct-to-consumer (DTC) marketing is working. New patient adds for the 365-day sensor are up nearly 100% YoY, driving an 87% YoY revenue increase.
🐻 Bear Case
The $5.4M YoY gain in gross profit was entirely erased by a $22.5M YoY explosion in SG&A expenses. The company spent $2.58 in SG&A for every $1 of revenue generated.
To fund the $32.3M quarterly burn rate, the company raised $92M in fresh equity. This extends the runway but heavily dilutes existing shareholders.
⚖️ Verdict: ⚪
Neutral. The top-line execution and gross margin expansion are excellent, validating the Eversense 365 demand. However, the sheer cost of running an independent commercial organization raises serious questions about the long-term path to profitability.
Key Themes
SG&A Explosion Contradicts Margin Narrative
Reversing. Management proudly highlighted a 59% gross margin (up from 24% YoY), framing the Ascensia commercial transition as a massive win. However, this narrative ignores the operating line: SG&A jumped 292% YoY to $30.2M. The net result is that operating loss actually worsened dramatically from $13.5M in 25Q1 to $31.8M in 26Q1. The company essentially bought its gross margin improvement by absorbing massive fixed sales and marketing costs.
Direct-to-Consumer Engine is Working
Accelerating. U.S. revenue doubled YoY to $9.3M. The aggressive direct-to-consumer (DTC) marketing strategy is successfully driving leads, with DTC new patient adds up nearly 100% YoY. As long as the company can afford the ad spend, the 365-day value proposition is clearly resonating with switchers from competitors.
European Expansion Unlocked
Accelerating. Following CE Mark approval in January, Senseonics initiated the commercial launch of Eversense 365 in Europe, starting with Sweden in April. This opens a significant new geographic market that should begin contributing meaningfully to the OUS revenue line ($2.4M in 26Q1) over the coming quarters.
Automated Insulin Delivery Integration
Accelerating. The integration with Sequel's twiist™ Automated Insulin Delivery (AID) system has officially launched. This technological milestone is critical, as it provides access to the lucrative Type 1 patient demographic that requires insulin pump compatibility, representing a major competitive catch-up to Dexcom and Libre.
Favorable Macro Reimbursement Environment
Stable. Continued adoption is heavily supported by the macro regulatory landscape, specifically the CMS Medicare Physician Fee Schedule updates that allow bundled payments for a full year of Eversense usage. This unique reimbursement structure makes the product financially attractive for participating clinics.
Persistent Cash Burn and Dilution
Stable. The company reported a net loss of $32.3M. To sustain operations, Senseonics raised $92M in growth capital via a public offering and amended its Hercules debt facility ($35.2M outstanding). While total cash sits at $64.6M, the sheer pace of the cash burn guarantees that capital markets will remain a looming risk for shareholders.
Sequential Revenue Seasonality
Decelerating. While YoY growth was 87%, total revenue dropped sequentially from $14.3M in 25Q4 to $11.7M in 26Q1. This reflects the standard Q1 medical device seasonality due to insurance deductible resets, which impacts patient purchasing behavior and forces the company to rely on back-half weighting to hit annual guidance.
Other KPIs
Accelerating. Up from $7.3M a year ago. Management continues to invest heavily in its innovation pipeline, including clinical trials for the next-generation Gemini (self-powered, 1-year) and Freedom (invisible) systems.
Accelerating. More than doubled from $4.5M in 25Q1, showcasing the impact of bringing commercial distribution in-house and aggressively pursuing DTC marketing channels.
Guidance
Accelerating. Management raised the bottom and top ends of the guidance range (previously $58-$62M). The midpoint implies a robust 76% YoY growth rate over FY25's $35.3M. This assumes successful scale-up of the internal commercial team and traction from the European launch.
Accelerating. Guidance implies a massive structural shift in profitability compared to historical ~25-40% margins, driven by recognizing 100% of the sale price post-Ascensia transition and improved manufacturing efficiencies.
Key Questions
SG&A Run Rate
SG&A came in at $30.2M for the quarter. How much of this includes one-time transition costs versus recurring fixed costs for the new internal commercial organization?
European Tender Dynamics
With the first insertions happening in Sweden, what is the timeline for securing national tender contracts in larger markets like Germany, Italy, and Spain?
Twiist AID Uptake
Now that the twiist AID system integration is live, what percentage of new patient starts are citing pump integration as their primary reason for choosing Eversense 365?